Articles From: Avanir Pharmaceuticals Announces Publication of Pivotal Phase III Results from AVP-825 Acute Migraine Study in the Journal "Headache" to Avery Dennison Announces Third Quarter 2014 Results


ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals Cancels Previously Scheduled Earnings Call investment picks
--Company Plans to Complete a New Human Factor Validation Study and Respond to the CRL in the First Half of Calendar 2015--
Sign-up for Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA investment picks
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Avanir Pharmaceuticals, Inc. NEW YORK , Dec.
Sign-up for AVANIR PHARMACEUTICALS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Avanir Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Otsuka Pharmaceutical Co., Ltd. - AVNR investment picks
ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals To Be Acquired By Otsuka Pharmaceutical For $3.5 Billion investment picks
- Meeting and Webcast to Begin at 7:30 a.m. Eastern Time - ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals to Host Investor Briefing on October 15, 2014 investment picks
ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals to Participate in Two Conferences in December investment picks
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Avanir Pharmaceuticals, Inc. (“Avanir”) (NASDAQ:AVNR) concerning the sale to Otsuka Pharmaceutical Co., Ltd.
Sign-up for AVANIR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Otsuka Pharmaceutical Co., Ltd. investment picks
2014/12/4
Rigrodsky & Long, P.A.: Do you own shares of Avanir Pharmaceuticals, Inc. (NASDAQ GS: AVNR )? Did you purchase any of your shares prior to December 2, 2014?
Sign-up for AVANIR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/12/2
WILMINGTON, Del.
Sign-up for AVANIR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
Avcorp announces 2014 Third Quarter Financial Results Canada NewsWire VANCOUVER , Nov.
Sign-up for Avcorp announces 2014 Third Quarter Financial Results investment picks
VANCOUVER , Nov.
Sign-up for Avcorp announces 2014 Third Quarter Financial Results investment picks
Avcorp announces appointment of Chief Executive Officer for its group of companies Canada NewsWire VANCOUVER , Oct.
Sign-up for Avcorp announces appointment of Chief Executive Officer for its group of companies investment picks
2014/10/9
Miami's Fourth Most-Visited Attraction Expands Amenities for International Visitors AVENTURA, Fla.
Sign-up for Aventura Mall Launches International Shipping Service investment picks
NEW YORK , Dec.
Sign-up for Avenue Income Credit Strategies Fund December Monthly Dividend investment picks
NEW YORK , Nov.
Sign-up for Avenue Income Credit Strategies Fund November Monthly Dividend investment picks
NEW YORK , Nov.
Sign-up for Avenue Income Credit Strategies Fund November Monthly Dividend - Revised investment picks
NEW YORK , Nov.
Sign-up for Avenue Income Credit Strategies Fund Portfolio Data investment picks
AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO’s HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSA®) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC). The results, presented in a poster session (abstract #8195) at the 2014 Congress of the European Society for Medical Oncology (ESMO), suggest that VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
Sign-up for AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress investment picks
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
Sign-up for AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases investment picks
AVEO Oncology (NASDAQ:AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company’s headquarters in Cambridge, Massachusetts, reducing its existing lease obligations by $110 million.
Sign-up for AVEO Oncology Announces Lease Termination and Amendment to Debt Financing Facility investment picks
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2 nd Cancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada.
Sign-up for AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference investment picks
AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25–30 in Madrid, Spain.
Sign-up for AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress investment picks
AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan.
Sign-up for AVEO Oncology Reports Third Quarter 2014 Financial Results investment picks
2014/11/20
By Justin Baer Wall Street pay will rise slightly this year, though the increase will be offset at some banks by huge legal settlements agreed to this year, an industry recruiter said in a new study to be released later this month.
Sign-up for Average Wall St. Pay to Rise 4% This Year -- Update investment picks
2014/11/20
By Justin Baer Wall Street pay will rise slightly this year, though the increase will be offset at some banks by huge legal settlements agreed to this year, an industry recruiter said in a new study to be released later this month.
Sign-up for Average Wall Street pay to rise 4% this year investment picks
FXT Edge Filers and Lattus Enable High-Performance, Cost-Effective Access to Content PITTSBURGH and SAN JOSE, Calif.
Sign-up for Avere and Quantum Team to Optimize Storage for Upstream Workflows in Oil and Gas Exploration investment picks
Avery Dennison Corporation (NYSE:AVY) today announced preliminary, unaudited results for its third quarter ended September 27, 2014.
Sign-up for Avery Dennison Announces Third Quarter 2014 Results investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Avanir Pharmaceuticals Announces Publication of Pivotal Phase III Results from AVP-825 Acute Migraine Study in the Journal "Headache" to Avery Dennison Announces Third Quarter 2014 Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent